
1. Biochimie. 2021 Oct 25. pii: S0300-9084(21)00249-2. doi:
10.1016/j.biochi.2021.10.013. [Epub ahead of print]

Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein
and various specific monoclonal antibodies.

Martí D(1), Alsina M(2), Alemán C(3), Bertran O(4), Turon P(5), Torras J(6).

Author information: 
(1)Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, 
C/ Eduard Maristany, 10-14, Ed. I2, 08019, Barcelona, Spain; Barcelona Research
Center in Multiscale Science and Engineering, Universitat Politècnica de
Catalunya, C/ Eduard Maristany, 10-14, 08019, Barcelona, Spain.
(2)Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, 
C/ Eduard Maristany, 10-14, Ed. I2, 08019, Barcelona, Spain.
(3)Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, 
C/ Eduard Maristany, 10-14, Ed. I2, 08019, Barcelona, Spain; Barcelona Research
Center in Multiscale Science and Engineering, Universitat Politècnica de
Catalunya, C/ Eduard Maristany, 10-14, 08019, Barcelona, Spain. Electronic
address: carlos.aleman@upc.edu.
(4)Departament de Física EETAC, Universitat Politècnica de Catalunya, c/ Esteve
Terrades, 7, 08860, Castelldefels, Spain.
(5)B. Braun Surgical, S.A.U. Carretera de Terrassa 121, 08191, Rubí (Barcelona), 
Spain. Electronic address: pau.turon@bbraun.com.
(6)Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, 
C/ Eduard Maristany, 10-14, Ed. I2, 08019, Barcelona, Spain; Barcelona Research
Center in Multiscale Science and Engineering, Universitat Politècnica de
Catalunya, C/ Eduard Maristany, 10-14, 08019, Barcelona, Spain. Electronic
address: joan.torras@upc.edu.

Vaccination against SARS-CoV-2 just started in most of the countries. However,
the development of specific vaccines against SARS-CoV-2 is not the only approach 
to control the virus and monoclonal antibodies (mAbs) start to merit special
attention as a therapeutic option to treat COVID-19 disease. Here, the main
conformations and interactions between the receptor-binding domain (RBD) of spike
glycoprotein of SARS-CoV-2 (S protein) with two mAbs (CR3022 and S309) and the
ACE2 cell receptor are studied as the main representatives of three different
epitopes on the RBD of S protein. The combined approach of 1 μs accelerated
molecular dynamics (aMD) and ab-initio hybrid molecular dynamics is used to
identify the most predominant interactions under physiological conditions.
Results allow to determine the main receptor-binding mapping, hydrogen bonding
network and salt bridges in the most populated antigen-antibody interface
conformations. The deep knowledge on the protein-protein interactions involving
mAbs and ACE2 receptor with the spike glycoprotein of SARS-CoV-2 increases
background knowledge to speed up the development of new vaccines and therapeutic 
drugs.

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

DOI: 10.1016/j.biochi.2021.10.013 
PMCID: PMC8545699
PMID: 34710552 

Conflict of interest statement: Declaration of competing interest The authors
declare no conflict of interest either financial, personal or other.

